2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
- Resource Type
- Abstract
- Authors
- Gettinger, S.; Schenker, M.; De Langen, J.; Fischer, J.R.; Morgensztern, D.; Ciuleanu, T-E.; Beck, T.; De Castro Carpeno, J.; Schumann, C.; Yang, X.; Telivala, B.; Deschepper, K.; Nadal, E.; Schalper, K.; Spires, T.; Balli, D.; Nassar, A.; Karam, S.; Bhingare, A.; Spigel, D.R.
- Source
- In Immuno-Oncology and Technology December 2022 16 Supplement 1
- Subject
- Language
- ISSN
- 2590-0188